Biopharma firm Boehringer Ingelheim, life science firm Evotec, and IVD firm BioMérieux have announced a joint venture to develop the next generation of antimicrobial medications and diagnostic tests to fight antimicrobial resistance.
Boehringer Ingelheim said Wednesday that the resulting company, Aurobac Therapeutics, will combine the capabilities of the three founding companies to develop a new precision medicine approach.
"Our role within the joint venture is to develop and commercialize diagnostic tests, including companion diagnostics, which deliver rapid, reliable, and actionable results," BioMérieux Chairman and CEO Alexandre Mérieux said in a statement.
